Pear Therapeutics, Inc., the leader in Prescription Digital Therapeutics (PDTs), announced today that it has entered into agreements with multiple technology innovators, including Firsthand Technology, Inc., leading researchers from the Karolinska Institute in Sweden, Cincinnati Children’s Hospital Medical Center, Winterlight Labs, Inc., and NeuroLex Laboratories, Inc. These new agreements continue to bolster Pear’s PDT platform, by adding to its library of digital biomarkers, machine learning algorithms, and digital therapeutics.
The study, which was presented at the Meeting of the American College of Neuropsychopharmacology yesterday, found that patients using the technology improved their sustained attention compared to those in the control group.
Astellas Pharma Inc. and Welldoc, Inc. today announced that the companies have entered into a collaboration and license agreement directed toward the development and commercialization of digital health solutions. Under the agreement, Astellas and Welldoc will jointly develop and commercialize BlueStar® in Japan and certain other Asian markets for patients with diabetes, collaborate to broaden the adoption of BlueStar® in the U.S. market, and jointly develop and commercialize digital therapeutics in other therapeutic areas globally.
Propeller Health, a leading digital health company dedicated to the management of asthma and chronic obstructive pulmonary disease (COPD), announced that users are now able to access pharmacy services from CVS, Walmart, Kroger and Rite Aid directly from the Propeller app.
In January 2019, Propeller announced the launch of My Pharmacy, an in-app feature that allows users to manage their prescription refills for asthma and COPD and locate a nearby pharmacy from the Propeller app.
DarioHealth Corp. (Nasdaq: DRIO) (“DarioHealth” or “Dario”), a leading global, digital therapeutics company, presented new clinical data yesterday at the 19th Annual Diabetes Technology Meeting (“DTM”) conference in Bethesda, Maryland, which showed remarkable improvements in average blood glucose levels (BGavg) and in-range measurements in patients with diabetes using Dario’s digital therapeutics platform and dedicated one-on-one personal health coaching.
DarioHealth’s digital therapeutics platform delivers personalized, evidence-based interventions to users that are driven by precision data analytics, high quality software and one-on-one coaching, which are all available through Dario’s suite of membership plans. The clinical study data presented at the DTM conference included users enrolled in Dario’s full membership plan, which is available to payers, providers and consumers.
Deepening a collaboration that began in 2013, Omada Health and Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced the availability of Omada’s Type 2 Diabetes Digital Care program as a covered benefit for the insurer’s commercial plans. Building on the two organizations’ success deploying digital diabetes prevention in the state, Omada’s type 2 diabetes program will be available for Minnesota employers to launch beginning January 2020. Blue Cross also announced a strategic investment in Omada Health through the insurer’s parent company.
A wrist-worn medical device — called the Personal KinetiGraph or PKG — that reminds people with Parkinson’s disease to take their medication, and records their movements to provide physicians with objective measurements of motor symptoms, showed great promise as a tool to improve clinical decision-making, a study found.
When worn for six days before a routine care visit, the device reported disease-related motor symptoms, like dyskinesia — involuntary muscle movement — and bradykinesia, or the progressive slowness of movement over time, even when patients did not report such symptoms.
Pear Therapeutics, Inc. announced today that it has entered into an agreement with Ironwood Pharmaceuticals, Inc. to evaluate Prescription Digital Therapeutics (PDTs) for the treatment of selected indications within the gastrointestinal (GI) space.
This collaboration will leverage Pear’s platform and capabilities in PDTs with Ironwood’s innovative GI franchise expertise.
“We are excited to be partnering with Ironwood on this initiative and believe there is a compelling clinical rationale for use of PDTs in treating GI diseases,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “This represents an important step for Pear and broadens our pipeline to diseases outside the central nervous system and into a range of chronic conditions.”
Starting today, Propeller users will be able to “ring” the sensor on a misplaced inhaler to make it easier to find, through an update to the Find My Inhaler feature in the Propeller app.
Propeller is a digital health tool that helps people with asthma or COPD manage their breathing. Propeller sensors connect to patients’ existing inhalers and transmit data on medication use and health patterns to the Propeller app on patients’ smartphones. This is the latest update from Propeller aimed at making life better for people with asthma or COPD, based on feedback from patients about the day-to-day realities of their condition.
Cognoa, a Palo Alto, CA-based pediatric behavioral health company developing digital medicines, announced the launch of a pivotal study of its digital diagnostic aid for autism. The results of this pivotal study will be the basis for the submission to FDA next year.
Study of Diagnostic Aid for Autism
Cognoa is developing AI-powered digital therapeutics and medicines to advance the standard of care in pediatric behavioral health and improve lifelong outcomes for children. The study is intended to enable pediatricians and physicians in primary care settings to make an autism diagnosis in children as young as 18 months, so that children can receive earlier treatment.